The University of Southampton
University of Southampton Institutional Repository
Warning ePrints Soton is experiencing an issue with some file downloads not being available. We are working hard to fix this. Please bear with us.

Enzyme potentiated desensitisation in treatment of seasonal allergic rhinitis: double blind randomised controlled study

Enzyme potentiated desensitisation in treatment of seasonal allergic rhinitis: double blind randomised controlled study
Enzyme potentiated desensitisation in treatment of seasonal allergic rhinitis: double blind randomised controlled study
Objective To assess the efficacy of enzyme potentiated desensitisation in the treatment of severe summer hay fever poorly controlled by pharmacotherapy.
Design Double blind randomised placebo controlled parallel group study.
Setting Hospital in Hampshire.
Participants 183 participants aged between 18 and 64 with a history of severe summer hay fever for at least two years; all were skin prick test positive to timothy grass pollen. 90 randomised to active treatment; 93 randomised to placebo.
Interventions Active treatment: two injections of enzyme potentiated desensitisation, given between eight and 11 weeks apart, each comprising 200 Fishman units of glucuronidase, 50 pg 1,3-cyclohexanediol, 50 ng protamine sulphate, and a mixed inhaled allergen extract (pollen mixes for trees, grasses, and weeds; allergenic fungal spores; cat and dog danders; dust and storage mites) in a total volume of 0.05 ml of buffered saline. Placebo: two injections of 0.05 ml buffered saline solution.
Main outcome measures Proportion of problem-free days; global rhinoconjunctivitis quality of life scores assessed weekly during pollen season.
Results The active treatment group and the placebo group did not differ in the proportion of problem-free days, quality of life scores, symptom severity scores, change in quantitative skin prick provocation threshold, or change in conjunctival provocation threshold. No clinically significant adverse reactions occurred.
Conclusions Enzyme potentiated desensitisation showed no treatment effect in this study.
0959-8138
251-254
Radcliffe, Michael J.
0301e5d9-7ee1-4fbe-b506-307940920cdb
Lewith, George T.
0fc483fa-f17b-47c5-94d9-5c15e65a7625
Turner, Richard G.
eabe17f4-848a-455c-b931-14ddd9f42b3a
Prescott, Phillip
cf0adfdd-989b-4f15-9e60-ef85eed817b2
Church, Martin K.
dad189d5-866e-4ae1-b005-0d87f74282b8
Holgate, Stephen T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Radcliffe, Michael J.
0301e5d9-7ee1-4fbe-b506-307940920cdb
Lewith, George T.
0fc483fa-f17b-47c5-94d9-5c15e65a7625
Turner, Richard G.
eabe17f4-848a-455c-b931-14ddd9f42b3a
Prescott, Phillip
cf0adfdd-989b-4f15-9e60-ef85eed817b2
Church, Martin K.
dad189d5-866e-4ae1-b005-0d87f74282b8
Holgate, Stephen T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc

Radcliffe, Michael J., Lewith, George T., Turner, Richard G., Prescott, Phillip, Church, Martin K. and Holgate, Stephen T. (2003) Enzyme potentiated desensitisation in treatment of seasonal allergic rhinitis: double blind randomised controlled study. BMJ, 327 (7409), 251-254. (doi:10.1136/bmj.327.7409.251).

Record type: Article

Abstract

Objective To assess the efficacy of enzyme potentiated desensitisation in the treatment of severe summer hay fever poorly controlled by pharmacotherapy.
Design Double blind randomised placebo controlled parallel group study.
Setting Hospital in Hampshire.
Participants 183 participants aged between 18 and 64 with a history of severe summer hay fever for at least two years; all were skin prick test positive to timothy grass pollen. 90 randomised to active treatment; 93 randomised to placebo.
Interventions Active treatment: two injections of enzyme potentiated desensitisation, given between eight and 11 weeks apart, each comprising 200 Fishman units of glucuronidase, 50 pg 1,3-cyclohexanediol, 50 ng protamine sulphate, and a mixed inhaled allergen extract (pollen mixes for trees, grasses, and weeds; allergenic fungal spores; cat and dog danders; dust and storage mites) in a total volume of 0.05 ml of buffered saline. Placebo: two injections of 0.05 ml buffered saline solution.
Main outcome measures Proportion of problem-free days; global rhinoconjunctivitis quality of life scores assessed weekly during pollen season.
Results The active treatment group and the placebo group did not differ in the proportion of problem-free days, quality of life scores, symptom severity scores, change in quantitative skin prick provocation threshold, or change in conjunctival provocation threshold. No clinically significant adverse reactions occurred.
Conclusions Enzyme potentiated desensitisation showed no treatment effect in this study.

This record has no associated files available for download.

More information

Published date: 2 August 2003

Identifiers

Local EPrints ID: 27347
URI: http://eprints.soton.ac.uk/id/eprint/27347
ISSN: 0959-8138
PURE UUID: bc5867dd-bd15-41b5-8462-774312196a5b

Catalogue record

Date deposited: 27 Apr 2006
Last modified: 08 Jan 2022 09:54

Export record

Altmetrics

Contributors

Author: Michael J. Radcliffe
Author: George T. Lewith
Author: Richard G. Turner
Author: Martin K. Church

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×